JP2004523555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004523555A5 JP2004523555A5 JP2002567292A JP2002567292A JP2004523555A5 JP 2004523555 A5 JP2004523555 A5 JP 2004523555A5 JP 2002567292 A JP2002567292 A JP 2002567292A JP 2002567292 A JP2002567292 A JP 2002567292A JP 2004523555 A5 JP2004523555 A5 JP 2004523555A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- formula
- disease
- group
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 35
- 208000015122 neurodegenerative disease Diseases 0.000 claims 18
- 208000014674 injury Diseases 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 208000027418 Wounds and injury Diseases 0.000 claims 11
- 230000006378 damage Effects 0.000 claims 11
- 230000001684 chronic effect Effects 0.000 claims 10
- 230000001154 acute effect Effects 0.000 claims 8
- 206010012289 Dementia Diseases 0.000 claims 6
- 206010008118 cerebral infarction Diseases 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 239000000460 chlorine Substances 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 208000029028 brain injury Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 206010021143 Hypoxia Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000028867 ischemia Diseases 0.000 claims 4
- 230000003902 lesion Effects 0.000 claims 4
- 201000001119 neuropathy Diseases 0.000 claims 4
- 230000007823 neuropathy Effects 0.000 claims 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 201000006474 Brain Ischemia Diseases 0.000 claims 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 208000034656 Contusions Diseases 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 208000034693 Laceration Diseases 0.000 claims 3
- 230000009692 acute damage Effects 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 230000006835 compression Effects 0.000 claims 3
- 238000007906 compression Methods 0.000 claims 3
- 230000009519 contusion Effects 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 230000007850 degeneration Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 230000002124 endocrine Effects 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 230000001146 hypoxic effect Effects 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 239000011630 iodine Substances 0.000 claims 3
- 230000001537 neural effect Effects 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 claims 2
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 claims 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 230000016273 neuron death Effects 0.000 claims 2
- 208000021090 palsy Diseases 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000032527 type III spinal muscular atrophy Diseases 0.000 claims 2
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims 1
- 102000007371 Ataxin-3 Human genes 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 1
- 206010050389 Cerebral ataxia Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000001730 Familial dysautonomia Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 claims 1
- 208000027747 Kennedy disease Diseases 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 208000034800 Leukoencephalopathies Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 240000007817 Olea europaea Species 0.000 claims 1
- 206010033885 Paraparesis Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000019155 Radiation injury Diseases 0.000 claims 1
- 208000005587 Refsum Disease Diseases 0.000 claims 1
- 201000001638 Riley-Day syndrome Diseases 0.000 claims 1
- 208000021811 Sandhoff disease Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims 1
- 208000032859 Synucleinopathies Diseases 0.000 claims 1
- 208000022292 Tay-Sachs disease Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 206010063661 Vascular encephalopathy Diseases 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000030597 adult Refsum disease Diseases 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000025434 cerebellar degeneration Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 210000003792 cranial nerve Anatomy 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 230000003073 embolic effect Effects 0.000 claims 1
- 230000008175 fetal development Effects 0.000 claims 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 206010023497 kuru Diseases 0.000 claims 1
- 208000037805 labour Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 238000011458 pharmacological treatment Methods 0.000 claims 1
- 208000001282 primary progressive aphasia Diseases 0.000 claims 1
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 claims 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27168201P | 2001-02-27 | 2001-02-27 | |
| US10/081,764 US20020165273A1 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| PCT/US2002/005541 WO2002067925A1 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004523555A JP2004523555A (ja) | 2004-08-05 |
| JP2004523555A5 true JP2004523555A5 (https=) | 2005-12-22 |
| JP4276840B2 JP4276840B2 (ja) | 2009-06-10 |
Family
ID=26765943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002567292A Expired - Fee Related JP4276840B2 (ja) | 2001-02-27 | 2002-02-21 | 神経変性障害の予防もしくは治療における使用のためのカルバメート化合物 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20020165273A1 (https=) |
| EP (1) | EP1383489B1 (https=) |
| JP (1) | JP4276840B2 (https=) |
| KR (1) | KR100910928B1 (https=) |
| CN (1) | CN1235579C (https=) |
| AR (1) | AR035756A1 (https=) |
| AT (1) | ATE361745T1 (https=) |
| BR (1) | BR0207645A (https=) |
| CA (1) | CA2439295C (https=) |
| CY (1) | CY1106753T1 (https=) |
| CZ (1) | CZ301203B6 (https=) |
| DE (1) | DE60220043T2 (https=) |
| DK (1) | DK1383489T3 (https=) |
| ES (1) | ES2284845T3 (https=) |
| HU (1) | HUP0303264A3 (https=) |
| IL (2) | IL157591A0 (https=) |
| MX (1) | MXPA03007718A (https=) |
| MY (1) | MY138156A (https=) |
| NO (1) | NO20033798L (https=) |
| NZ (1) | NZ527990A (https=) |
| PL (1) | PL364680A1 (https=) |
| PT (1) | PT1383489E (https=) |
| RS (1) | RS51055B (https=) |
| RU (1) | RU2300373C2 (https=) |
| TW (1) | TWI312679B (https=) |
| WO (1) | WO2002067925A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033093A1 (en) * | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| CA2580640A1 (en) * | 2004-09-16 | 2006-03-30 | Janssen Pharmaceutica N.V. | Methods of treating epileptogensis and epilepsy |
| MX2007004491A (es) * | 2004-10-15 | 2007-08-08 | Johnson & Johnson | Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos. |
| US20070021500A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods for neuroprotection |
| AU2005335241B9 (en) * | 2005-07-26 | 2012-12-20 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating substance-related disorders |
| CN101657195A (zh) * | 2006-10-06 | 2010-02-24 | 詹森药业有限公司 | 氨基甲酸(s)-(+)-2-(2-氯代苯基)-2-羟基乙酯的新型晶体 |
| CA2667949A1 (en) * | 2006-10-30 | 2008-05-08 | Janssen Pharmaceutica N.V. | Methods for treating depression |
| MX2009004798A (es) * | 2006-10-31 | 2009-08-12 | Janssen Pharmaceutica Nv | Tratamiento de los trastornos generalizados del desarrollo. |
| CA2803825C (en) * | 2010-07-02 | 2015-12-29 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate compound and muscle relaxant containing the same |
| US9018253B2 (en) | 2010-07-02 | 2015-04-28 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate compound and muscle relaxant containing the same |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| US20130060024A1 (en) * | 2011-09-07 | 2013-03-07 | Satori Pharmaceuticals, Inc. | Compounds useful for treating neurodegenerative disorders |
| EP2797880B1 (en) * | 2011-12-27 | 2017-03-01 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compounds for use in preventing or treating epilepsy |
| EP2968210B1 (en) * | 2013-03-12 | 2024-09-11 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compounds for use in preventing or treating pediatric epilesy |
| US9566261B2 (en) | 2013-03-12 | 2017-02-14 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compound and a composition for preventing or treating a memory loss-related disease comprising the same |
| ES3059582T3 (en) | 2016-02-29 | 2026-03-23 | Bio Pharm Solutions Co Ltd | Sulfamate derivative compounds, processes for preparing them and their uses |
| ES3035674T3 (en) | 2016-12-14 | 2025-09-08 | Sk Biopharmaceuticals Co Ltd | Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease |
| US20220117941A1 (en) * | 2018-09-21 | 2022-04-21 | Sk Biopharmaceuticals Co., Ltd. | Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder |
| JP2023539291A (ja) * | 2020-08-31 | 2023-09-13 | バイオ－ファーム ソリューションズ カンパニー リミテッド | 神経変性疾患の予防又は治療用フェニルアルキルカルバメート化合物 |
| KR20230051206A (ko) | 2020-09-10 | 2023-04-17 | (주)바이오팜솔루션즈 | 정신질환 치료 또는 완화용 설파메이트 유도체 화합물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) * | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3278380A (en) * | 1962-02-06 | 1966-10-11 | Armour Pharma | Methods of calming employing diphenyl hydroxy carbamate compounds |
| US3265728A (en) * | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| US5474990A (en) * | 1989-10-20 | 1995-12-12 | Olney; John W. | Barbiturates as safening agents in conjunction with NMDA antagonists |
| CN1109880A (zh) * | 1994-02-03 | 1995-10-11 | 合成实验室公司 | 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用 |
| US5492930A (en) * | 1994-04-25 | 1996-02-20 | Schering Corporation | Method and formulation for treating CNS disorders |
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| US5728728A (en) * | 1996-04-10 | 1998-03-17 | Kozachuk; Walter E. | Methods of providing neuroprotection |
| US6232434B1 (en) * | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
| MXPA03007717A (es) * | 2001-02-27 | 2005-11-08 | Johnson & Johnson | Compuestos de carbamato para su uso en la prevencion o tratamiento de trastornos bipolares. |
| CN1262272C (zh) * | 2001-02-27 | 2006-07-05 | 奥索-麦克尼尔药品公司 | 用于预防或治疗运动障碍的氨基甲酸酯化合物 |
| US6541513B2 (en) * | 2001-02-27 | 2003-04-01 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating psychotic disorders |
-
2002
- 2002-02-21 PL PL02364680A patent/PL364680A1/xx unknown
- 2002-02-21 BR BR0207645-4A patent/BR0207645A/pt not_active Application Discontinuation
- 2002-02-21 CZ CZ20032313A patent/CZ301203B6/cs not_active IP Right Cessation
- 2002-02-21 PT PT02714977T patent/PT1383489E/pt unknown
- 2002-02-21 CN CNB028087178A patent/CN1235579C/zh not_active Expired - Fee Related
- 2002-02-21 JP JP2002567292A patent/JP4276840B2/ja not_active Expired - Fee Related
- 2002-02-21 ES ES02714977T patent/ES2284845T3/es not_active Expired - Lifetime
- 2002-02-21 MX MXPA03007718A patent/MXPA03007718A/es active IP Right Grant
- 2002-02-21 WO PCT/US2002/005541 patent/WO2002067925A1/en not_active Ceased
- 2002-02-21 DE DE60220043T patent/DE60220043T2/de not_active Expired - Lifetime
- 2002-02-21 RS YUP-674/03A patent/RS51055B/sr unknown
- 2002-02-21 HU HU0303264A patent/HUP0303264A3/hu unknown
- 2002-02-21 NZ NZ527990A patent/NZ527990A/en unknown
- 2002-02-21 IL IL15759102A patent/IL157591A0/xx unknown
- 2002-02-21 AT AT02714977T patent/ATE361745T1/de active
- 2002-02-21 KR KR1020037011302A patent/KR100910928B1/ko not_active Expired - Fee Related
- 2002-02-21 CA CA2439295A patent/CA2439295C/en not_active Expired - Fee Related
- 2002-02-21 RU RU2003128982/14A patent/RU2300373C2/ru not_active IP Right Cessation
- 2002-02-21 US US10/081,764 patent/US20020165273A1/en not_active Abandoned
- 2002-02-21 DK DK02714977T patent/DK1383489T3/da active
- 2002-02-21 EP EP02714977A patent/EP1383489B1/en not_active Expired - Lifetime
- 2002-02-27 MY MYPI20020697A patent/MY138156A/en unknown
- 2002-02-27 TW TW091103504A patent/TWI312679B/zh active
- 2002-02-27 AR ARP020100697A patent/AR035756A1/es unknown
-
2003
- 2003-08-26 IL IL157591A patent/IL157591A/en not_active IP Right Cessation
- 2003-08-26 NO NO20033798A patent/NO20033798L/no not_active Application Discontinuation
-
2004
- 2004-03-10 US US10/797,795 patent/US20040171679A1/en not_active Abandoned
-
2007
- 2007-07-24 CY CY20071100982T patent/CY1106753T1/el unknown
-
2008
- 2008-09-10 US US12/207,816 patent/US20090005442A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004523555A5 (https=) | ||
| JP2005501801A5 (https=) | ||
| RU2003128982A (ru) | Карбаматы для предотвращения или лечения нейродегенеративных нарушений | |
| KR101098480B1 (ko) | 3치환2（아릴알킬）1아자바이시클로알칸 및 그 사용방법 | |
| DK1303495T3 (da) | Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet | |
| HUP0100786A2 (hu) | Helyettesített 2-fenil-1-(3,4-dihidroxi-5-nitrofenil)-1-etanonok, felhasználásuk egyes központi és perifériás idegrendszeri betegségek kezelésére és e vegyületeket tartalmazó gyógyszerkészítmények | |
| JP2002516853A5 (https=) | ||
| JP2008514627A5 (https=) | ||
| EP2801366A3 (en) | Improved apo E analogs and methods for their use | |
| MXPA04005444A (es) | Ureas de 2-aminobenzotiazoles como moduladores de adenosina. | |
| MX2010004026A (es) | Piperidino-dihidrotienopirimidinas sustituidas. | |
| CY1112374T1 (el) | Επιλεκτικα του υποτυπου νικοτινικου υποδοχεα της ακετυλχολινης αμιδια διαζαδικυκλοαλκανιων | |
| PT2527315E (pt) | Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson | |
| CZ122598A3 (cs) | Použití 2-amino-4-/4-fluorbenzylamino/-ethoxykarbonylaminobenzenu pro profylaxi a léčení následků akutní a chronické mozkové nedokrevnosti jakož i neurodegenerativních onemocnění | |
| JP2009501224A5 (https=) | ||
| HRP20100304T1 (hr) | Uporaba 2-fenil-1,2-etanediol-(di)karbamata za liječenje epileptogeneze | |
| JP2010522711A5 (https=) | ||
| JP2022539152A5 (https=) | ||
| MA27591A1 (fr) | Agonistes du recepteur du facteur de liberation 2 de la corticotropine. | |
| TW200635589A (en) | Therapeutic agents | |
| JP2009501223A5 (https=) | ||
| PA8572601A1 (es) | Compuestos de 3,4-dihidroquinolin-2 (1h)-ona como antagonistas del receptor nr2b | |
| BRPI0816571A2 (pt) | "composto, processo para preparação do composto, composição farmacêutica, agente e método para o tratamento de uma doença ou uma desordem do sistema nervoso central relacionada à ou afetada pelo recptor 5-ht6" | |
| KR102467285B9 (ko) | 우황청심환을 포함하는 파킨슨 질환 예방 또는 치료용 약학 조성물 | |
| JP2019535715A5 (https=) |